Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1447-0756.1988.tb00141.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of mifepristone, a model compound with anti-progestogenic activity, on the reproduction of African clawed frog (Xenopus laevis).
J Hazard Mater
December 2024
University of South Bohemia in České Budějovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Research Institute of Fish Culture and Hydrobiology, Zátiší 728/II, 38925 Vodňany, Czech Republic. Electronic address:
This is the first study on how a substance with anti-progestogenic activity affects amphibian reproduction. Mifepristone, a synthetic anti-progestin used in abortion pills, was chosen as model compound. African clawed frog (Xenopus laevis) females were exposed to four mifepristone concentrations (0.
View Article and Find Full Text PDFAntiprogestins for breast cancer treatment: We are almost ready.
J Steroid Biochem Mol Biol
July 2024
Laboratory of Hormonal Carcinogenesis, Instituto de Biología y Medicina Experimental (IBYME CONICET), Buenos Aires, Argentina. Electronic address:
The development of antiprogestins was initially a gynecological purpose. However, since mifepristone was developed, its application for breast cancer treatment was immediately proposed. Later, new compounds with lower antiglucocorticoid and antiandrogenic effects were developed to be applied to different pathologies, including breast cancer.
View Article and Find Full Text PDFNext step in the development of mesoprogestins: the preclinical profile of EC313.
Front Endocrinol (Lausanne)
September 2023
Evestra, Inc., Corporate Headquarters, Schertz, TX, United States.
Article Synopsis
- EC313 is a novel Selective Progesterone Receptor Modulator (SPRM) that exhibits both agonistic and antagonistic properties on the nuclear progesterone receptor, showing potential advantages over existing treatments.
- The estrogen-primed juvenile rabbit endometrium assay demonstrates that EC313 has stronger PR-agonistic effects than other mesoprogestins like Asoprisnil, indicating its effectiveness for conditions like uterine fibroids and endometriosis.
- In preclinical studies, EC313 effectively inhibits estrogenic activity and demonstrates superior anti-ovulatory effects without inducing premature labor, making it a promising candidate for further development in reproductive health treatments.
Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles.
Biotechnol Rep (Amst)
June 2022
Nanotechnology and Regenerative Medicine Commercialization Centre (Ltd), London Innovation BioScience Centre, London, United Kingdom.
This review highlights using nanotechnology in increasing the bioavailability of AP (Apigenin) to enhance its therapeutic efficacy in breast cancer treatment. Breast cancer is one of the most leading causes of cancer death in women both in developed and developing countries. According to several epidemiological and clinical trial studies that indicate progestin-stimulated breast cancer in post-menopausal women; it is necessary to determine compounds to suppress or attenuate the tumor-promoting effects of progestins in breast cells.
View Article and Find Full Text PDFNew Selective Progesterone Receptor Modulators and Their Impact on the RANK/RANKL Complex Activity.
Molecules
March 2020
Department of Applied Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
Breast cancer depends on women's age. Its chemotherapy and hormone therapy lead to the loss of bone density and disruption of the skeleton. The proteins RANK and RANKL play a pivotal role in the formation of osteoclasts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!